Innoviva to Participate in the BofA Securities Health Care Conference
Innoviva to Participate in the BofA Securities Health Care Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--May 8, 2024-- Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the BofA Securities Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024 at 9:20 a.m. Pacific Daylight Time.
加利福尼亞州伯林格姆--(美國商業資訊)--2024年5月8日--Innoviva, Inc.（納斯達克股票代碼：INVA）（“Innoviva” 或 “公司”）是一家多元化控股公司，擁有核心特許權使用費組合、名爲Innoviva Specialty Therapeutics（“IST”）的領先重症監護和傳染病平台以及醫療資產戰略投資組合，今天宣佈，首席執行官帕維爾·雷菲爾德將出席美國銀行證券醫療保健會議將於2024年5月15日星期三太平洋夏令時間上午9點20分在內華達州拉斯維加斯舉行。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.
可以在公司網站投資者關係部分的 “活動與演講” 下觀看爐邊談話的網絡直播 https://investor.inva.com/presentations-events。網絡直播將在活動結束後的90天內重播。
About Innoviva
關於 Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
Innoviva是一家多元化的控股公司，擁有核心特許權使用費投資組合、名爲Innoviva Specialty Therapeutics（IST）的領先重症監護和傳染病平台以及對醫療資產的戰略投資組合。Innoviva的特許權使用費投資組合包括與葛蘭素集團有限公司（GSK）合作的呼吸資產。Innoviva有權從葛蘭素史克獲得銷售RELVAR/BREO ELLIPTA和ANORO ELLIPTA的特許權使用費。Innoviva的其他創新醫療資產包括因收購Entasis Therapeutics而產生的傳染病和重症監護資產，包括XACDURO（注射用舒巴坦；注射用度洛巴坦），經批准用於治療由鮑曼不動桿菌-鈣醋複合物敏感菌株引起的醫院獲得性細菌性肺炎和呼吸機相關細菌性肺炎的成年人，以及正在研究的目前正在開發用於治療無併發症的淋病的全效佐立氟達辛，拉霍亞製藥公司，包括GIAPREZA（血管緊張素II），獲准提高患有敗血症或其他分佈性休克的成人的血壓，並批准XERAVA（依拉環素）用於治療成人複雜的腹腔內感染。
ANORO, RELVAR, BREO and TRELEGY are trademarks of the GSK group of companies.
ANORO、RELVAR、BREO和TRELEGY是葛蘭素史克集團公司的商標。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508737674/en/
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Innoviva, Inc.
大衛帕蒂
企業傳播
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
投資者和媒體：
Argot Par
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
資料來源：Innoviva, Inc.
譯文內容由第三人軟體翻譯。